Share This
table started by
jame0taylor for the BioVenturist Base
There is no user-contributed description yet.
Add More Topics
Save this view to a base, or just for yourself.
699 BV: Therapeutic topics matching:
Filter this Collection
+
x
-
BV: Therapeutic
- » Target/Biomolecule of Interest
-
Indication or disease
- » therapeutic molecule
- » Delivery Technology
- Approval Date
-
Patent Expiration
-
BV: Product
-
Drug
-
Medical Treatment
-
veterinary drug
-
Chemical Compound
-
BV: Therapeutic Molecule
- Other Columns Other Info
|
|
|
|
||||||
|---|---|---|---|---|---|---|---|---|
| x name | x image | x Indication or disease | x Sales | x Developed by | x article | x Brand Names | ||
| x Disease | x Phase of development | x Amount | x Year | |||||
| x Actiq |
|
Breakthrough pain | On the market | 577,642,000 | 2006 | Cephalon |
Actiq by Cephalon, is a solid formulation of fentanyl citrate on a plastic stick that dissolves slowly in the mouth for absorption across the buccal mucosa. Generically Actiq is a form of oral transmucosal fentanyl citrate (OTFC). In the UK,...
|
Actiq |
| 240,072,000 | 2007 | |||||||
| 411,778,000 | 2005 | |||||||
| x ACTIVASE | 268,000,000 | 2007 | Genentech | Activase | ||||
| 218,000,000 | 2005 | |||||||
| 243,000,000 | 2006 | |||||||
| x Nifedipine |
|
Hypertension | On the market | 657,000,000 | 2006 | Bayer |
Nifedipine (brand name Adalat, Nifedical, and Procardia) is a dihydropyridine calcium channel blocker. Its main uses are as an antianginal (especially in Prinzmetal's angina) and antihypertensive, although a large number of other uses have recently...
|
Adalat |
| Angina | On the market | 614,000,000 | 2007 | |||||
| x Aldurazyme | Mucopolysaccharidosis I | On the market | Genzyme | Aldurazyme | ||||
| x ALKERAN | Multiple myeloma | On the market | 50,337,000 | 2006 | Celgene | Alkeran | ||
| Ovarian cancer | On the market | 49,748,000 | 2005 | |||||
| 73,551,000 | 2007 | |||||||
| x Ambisome | Fungal Infections | On the market | 262,571,000 | 2007 | Gilead Sciences | AmBisome | ||
| 223,031,000 | 2006 | Fujisawa | ||||||
| x Alefacept |
|
Astellas Pharma |
Alefacept is a genetically engineered immunosuppressive drug sold under the brand name Amevive in Canada, the United States, Israel, Switzerland and Australia. It is used to control inflammation in moderate to severe psoriasis with plaque formation,...
|
Amevive | ||||
| x Amevive | Plaque Psoriasis | On the market | 700,000 | 2007 | Biogen Idec |
Amevive is a drug that is used to treat certain skin conditions and is being studied in the treatment of cutaneous (skin-related) T-cell cancer and T-cell non-Hodgkin lymphoma. Amevive is made by combining part of an antibody with a protein that...
|
Amevive | |
| 20,700,000 | 2005 | |||||||
| 11,500,000 | 2006 | |||||||
| x Amrix | Muscle Spasms | On the market | 8,401,000 | 2007 | Cephalon | Amrix | ||
| x Etoricoxib | Chronic pain | On the market | 329,100,000 | 2007 | Merck & Co. |
Etoricoxib (brand name Arcoxia worldwide; also Algix and Tauxib in Italy) is a COX-2 selective inhibitor (approx. 106.0 times more selective for COX-2 inhibition over COX-1) from Merck & Co. Doses are 60, 90 mg/day for chronic pain and 120 mg/day...
|
Arcoxia | |
| Acute Pain | On the market | 218,200,000 | 2005 | |||||
| 265,400,000 | 2006 | |||||||
| x Donepezil | Alzheimer's disease | On the market | 401,000,000 | 2007 | Pfizer | Aricept | ||
| 358,000,000 | 2006 | |||||||
| 346,000,000 | 2005 | |||||||
| x Exemestane | Breast cancer | On the market | 320,000,000 | 2006 | Pfizer |
Exemestane (trade name Aromasin) is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. An aim in the...
|
Aromasin | |
| 247,000,000 | 2005 | |||||||
| 401,000,000 | 2007 | |||||||
| x Aspirin Cardio | Cardiovascular disease | On the market | 229,000,000 | 2007 | Bayer | Aspirin Cardio | ||
| Myocardial infarction | On the market | 209,000,000 | 2006 | |||||
| x Atarax | 55,000,000 | 2007 | UCB | Atarax | ||||
| 54,000,000 | 2006 | |||||||
| x Atmadisc | Asthma | On the market | 48,000,000 | 2007 | UCB | Atmadisc | ||
| 47,000,000 | 2006 | |||||||
| x Atripla | AIDS | On the market | 903,381,000 | 2007 | Gilead Sciences |
Atripla is a fixed dose combination drug for the treatment of HIV infection. It combines Gilead Sciences's tenofovir and emtricitabine (already available in the anti-HIV combination Truvada) with Bristol-Myers Squibb's efavirenz into a fixed-dose...
|
Atripla | |
| HIV infection | On the market | 205,729,000 | 2006 | |||||
| x Bevacizumab | Colorectal cancer | On the market | 1,133,000,000 | 2005 | Genentech |
Bevacizumab (trade name Avastin, Genentech/Roche) is a humanized monoclonal antibody that recognises and blocks vascular endothelial growth factor (VEGF). VEGF is a chemical signal that stimulates the growth of new blood vessels (angiogenesis)....
|
Avastin | |
| Non-Small Cell Lung Carcinoma | On the market | 1,746,000,000 | 2006 | |||||
| Breast cancer | On the market | 2,300,000,000 | 2007 | |||||
| B-cell lymphoma | Phase III Clinical Trial | |||||||
| Non-Squamous Non-Small Cell Lung Cancer | Phase II Clinical Trial | |||||||
| more ▼ | ||||||||
| x Moxifloxacin | Bronchitis | On the market | 445,000,000 | 2007 | Bayer |
Moxifloxacin is a third generation synthetic fluoroquinolone chemotherapeutic agent developed by Bayer AG (initially called BAY 12-8039). It is marketed worldwide (as the hydrochloride) under the brand names Avelox, Avalox and Avelon for oral...
|
Avelox | |
| Sinusitis | On the market | 396,000,000 | 2006 | |||||
| x Avonex | Multiple sclerosis | On the market | 1,706,700,000 | 2006 | Biogen Idec | Avonex | ||
| 1,867,800,000 | 2007 | |||||||
| 1,543,100,000 | 2005 | |||||||
| x Betaferon | Multiple sclerosis | On the market | 1,028,000,000 | 2007 | Bayer | Betaferon | ||
| 535,000,000 | 2006 | |||||||
| x Tositumomab | Follicular lymphoma | On the market | Corixa |
Tositumomab is a monoclonal antibody derived from immortalized mouse cells. It is a IgG2a anti-CD20 antibody and is covalently bound to I. I emits both beta and gamma radiation and decays with a half-life of 8 days.
Clinical trials have established...
|
Bexxar | |||
| x Exenatide | Diabetes mellitus type 2 | On the market | 636,000,000 | 2007 |
Exenatide (INN, marketed as Byetta) is one of a new class of medications (incretin mimetics) approved (Apr 2005) for the treatment of diabetes mellitus type 2. (It is not approved for use in diabetes mellitus type 1.) It is manufactured by Eli Lilly...
|
Byetta | ||
| 75,200,000 | 2005 | |||||||
| 430,200,000 | 2006 | |||||||
| x Caduet |
|
LDL Cholesterol Reduction | On the market | 185,000,000 | 2005 | Pfizer |
Caduet is a medication approved by the US FDA for the treatment of high cholesterol and high blood pressure. It is a fixed dose combination drug containing amlodipine, a calcium channel blocker (commonly sold as Norvasc), and atorvastatin (Lipitor)....
|
Caduet |
| Hypertension | On the market | 586,000,000 | 2007 | |||||
| 370,000,000 | 2006 | |||||||
| x Alemtuzumab |
|
Chronic lymphocytic leukemia | On the market | Genzyme |
Alemtuzumab (marketed as Campath, MabCampath or Campath-1H) is a monoclonal antibody used in the treatment of chronic lymphocytic leukemia (CLL), cutaneous T cell lymphoma (CTCL) and T-cell lymphoma.
Alemtuzumab targets CD52, a protein present on...
|
Campath | ||
| B-cell lymphoma | On the market | Bayer | ||||||
| Multiple sclerosis | Phase III Clinical Trial | |||||||
| x Irinotecan | Colorectal cancer | On the market | 969,000,000 | 2007 | Pfizer |
Irinotecan (Camptosar, Pfizer; Campto, Yakult Honsha) is a drug used for the treatment of cancer.
Irinotecan is a topoisomerase 1 inhibitor, which prevents DNA from unwinding. Chemically, it is a semisynthetic analogue of the natural alkaloid...
|
Camptosar | |
| 903,000,000 | 2006 | |||||||
| 910,000,000 | 2005 | |||||||
| x Caspofungin |
|
Fungal Infections | On the market | 570,000,000 | 2005 | Merck & Co. |
Caspofungin (INN) (brand name Cancidas worldwide) is an antifungal drug, the first of a new class termed the echinocandins from Merck & Co., Inc. It shows activity against infections with Aspergillus and Candida, and works by inhibiting the enzyme β...
|
Cancidas |
| 529,800,000 | 2006 | |||||||
| 536,900,000 | 2007 | |||||||
| x Doxazosin | Hypertension | On the market | 506,000,000 | 2007 | Pfizer |
Doxazosin mesylate, a quinazoline compound sold by Pfizer under the brand names Cardura and Carduran, is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.
On February 22, 2005, the US FDA approved a sustained...
|
Cardura | |
| Benigh Prostatic Hyperplasia | On the market | 538,000,000 | 2006 | |||||
| 586,000,000 | 2005 | |||||||
| x Carticel | Pain | On the market | Genzyme | Carticel | ||||
| x Arcitumomab |
Technetium (Tc) arcitumomab (trade name CEA-Scan) is a drug used to detect gastrointestinal cancers. It consists of a mouse monoclonal antibody (arcitumomab) and a radionuclide, technetium-99m.
Arcitumomab recognizes carcinoembryonic antigen (CEA),...
|
CEA-Scan | ||||||
| x Celecoxib |
|
Arthritis Pain | On the market | 2,039,000,000 | 2006 | Pfizer |
Celecoxib (INN) (pronounced /sɛlɨˈkɒksɪb/) is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce numbers of colon and...
|
Celebrex |
| Acute Pain | On the market | 2,290,000,000 | 2007 | |||||
| 1,730,000,000 | 2005 | |||||||
| x Cerezyme | Gaucher's disease | On the market | 1,100,000,000 | 2007 | Genzyme | Cerezyme | ||
| 932,300,000 | 2005 | |||||||
| 1,000,000,000 | 2006 | |||||||
| x Varenicline |
|
Smoking cessation | On the market | 101,000,000 | 2006 | Pfizer |
Varenicline (trade name Chantix in the USA and Champix in Europe and other countries, marketed by Pfizer, usually in the form of varenicline tartrate) is a prescription medication used to treat smoking addiction. Varenicline is a nicotinic receptor...
|
Chantix |
| 883,000,000 | 2007 | |||||||
| x Certolizumab pegol | Rheumatoid arthritis | Awaiting Approval | UCB |
Certolizumab pegol (CDP870, tradename Cimzia) is a therapeutic monoclonal antibody for the treatment of Crohn's disease produced by UCB . It is also investigated for use against rheumatoid arthritis.
Certolizumab pegol is a monoclonal antibody...
|
Cimzia | |||
| Crohn's disease | Awaiting Approval | |||||||
| Psoriasis | Phase II Clinical Trial | |||||||
| x Ciprofloxacin |
|
Bacterial Infection | On the market | 383,000,000 | 2007 | Bayer |
Ciprofloxacin (INN) is a drug used to treat bacterial infections. It is a second generation fluoroquinolone antibacterial. It kills bacteria by interfering with the enzymes that cause DNA to rewind after being copied, which stops DNA and protein...
|
Cipro |
| 513,000,000 | 2006 | Ciproxin | ||||||
| x Clofarabine | Acute lymphoblastic leukemia | On the market | Genzyme |
Clofarabine is a purine nucleoside antimetabolite marketed in the U.S. and Canada as Clolar. In Europe and Australia/New Zealand the product is marketed under the name Evoltra. It is FDA-approved for treating a type of leukaemia called relapsed or...
|
Clolar | |||
| Acute myeloid leukemia | Phase III Clinical Trial | |||||||
| x Copaxone | Teva Pharmaceutical Industries | Copaxone | ||||||
| x Cosopt | Ocular hypertension | On the market | 786,800,000 | 2007 | Merck & Co. |
Dorzolamide/timolol eyedrops (trade name Cosopt) are used for lowering pressure in the eye to normal levels, and a treatment for glaucoma. The drug is a combination of two chemicals: dorzolamide hydrochloride and timolol maleate. It gained Food and...
|
Cosopt | |
| Glaucoma | On the market | 697,100,000 | 2006 | |||||
| 617,200,000 | 2005 | |||||||
| x Losartan |
|
Hypertension | On the market | 3,037,200,000 | 2005 | Merck & Co. |
Losartan (rINN) (pronounced /loʊˈsɑrtən/) is an angiotensin II receptor antagonist drug used mainly to treat high blood pressure (hypertension). Losartan was the first angiotensin II receptor antagonist to be marketed. It is currently marketed by...
|
Cozaar |
| 3,163,100,000 | 2006 | |||||||
| 3,350,100,000 | 2007 | |||||||
| x Crixivan |
|
HIV infection | On the market | 310,200,000 | 2008 | Merck & Co. |
(indinavir sulfate) is a protease inhibitor from Merck and Co., Inc. It is part of HAART (Highly Active Anti-Retroviral Therapy)that reduces the viral load of HIV and raises CD4 (T) cell counts in some patients. It was approved by the Food and Drug...
|
Crixivan |
| 348,400,000 | 2006 | |||||||
| 327,300,000 | 2007 | |||||||
| x Deponit | Coronary heart disease | On the market | UCB | Deponit | ||||
| x Tolterodine |
|
Overactive bladder | On the market | 988,000,000 | 2005 | Pfizer |
Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. It is sold under the trade names Detrol and Detrusitol.
Tolterodine acts on M1, M2, M3, M4 and M5 subtypes of muscarinic receptors whereas modern antimuscarinic...
|
Detrol |
| 1,190,000,000 | 2007 | |||||||
| 1,100,000,000 | 2006 | |||||||
| x Diane | 88,000,000 | 2006 | Bayer | Diane | ||||
| 175,000,000 | 2007 | |||||||
| x Fluconazole |
|
Fungal Infections | On the market | 415,000,000 | 2007 | Pfizer |
Fluconazole (pronounced /fluːˈkɒnəzoʊl/) is a triazole antifungal drug used in the treatment and prevention of superficial and systemic fungal infections. In a bulk powder form, it appears as a white crystalline powder, and it is very slightly...
|
Diflucan |
| 498,000,000 | 2005 | |||||||
| 435,000,000 | 2006 | |||||||
| x Edex | Erectile dysfunction | On the market | UCB | Edex | ||||
| x Elvitegravir |
|
HIV infection | On the market | Gilead Sciences |
Elvitegravir (EVG) is an investigational new drug for the treatment of HIV infection. It acts as an integrase inhibitor. It is undergoing Phase III clinical trial conducted by the pharmaceutical company Gilead Sciences, which licensed EVG from Japan...
|
Elvitegravir | ||
| x Aprepitant |
|
Chemotherapy Induced Nausia | On the market | 204,200,000 | 2007 | Merck & Co. |
Aprepitant (Emend (US, EU)) is a chemical compound that belongs to a class of drugs called substance P antagonists (SPA). It mediates its effect by blocking the neurokinin 1 (NK1) receptor.
Aprepitant is manufactured by Merck & Co. under the brand...
|
Emend |
| 87,000,000 | 2005 | |||||||
| 130,800,000 | 2006 | |||||||
| x Emtricitabine |
|
AIDS | On the market | 36,393,000 | 2006 | Gilead Sciences |
Emtricitabine (FTC), with trade name Emtriva (formerly Coviracil), is a nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of HIV infection in adults and children.
Emtricitabine is also marketed in a fixed-dose combination with...
|
Emtriva |
| HIV infection | On the market | 31,493,000 | 2007 | |||||
| x Etanercept |
|
Rheumatoid arthritis | On the market | 2,879,000,000 | 2006 | Amgen |
Etanercept (Enbrel) is a drug that treats autoimmune diseases by interfering with the TNF receptor (a part of the immune system) by acting as a TNF inhibitor.
Etanercept is a fusion protein produced through expression of recombinant DNA. That is, it...
|
Enbrel |
| Ankylosing spondylitis | On the market | 3,230,000,000 | 2007 | |||||
| Psoriatic arthritis | On the market | 2,573,000,000 | 2005 | |||||
| Plaque Psoriasis | On the market | |||||||
| Juvenile idopathic arthritis | On the market | |||||||
| x Cetuximab | Colorectal cancer | On the market | 1,100,000,000 | 2006 | Bristol-Myers Squibb |
Cetuximab (IMC-C225 -- marketed under the name Erbitux) is a chimeric (mouse/human) monoclonal antibody, an epidermal growth factor receptor (EGFR) inhibitor, given by intravenous infusion for treatment of metastatic colorectal cancer and head and...
|
Erbitux | |
| 1,300,000,000 | 2007 | ImClone Systems | ||||||
| 4,130,000,000 | 2005 | |||||||
| x Fabrazyme | Fabry's disease | On the market | Genzyme | Fabrazyme | ||||
| x Fentora | Breakthrough pain | On the market | 29,250,000 | 2006 | Cephalon | Fentora | ||
| 135,136,000 | 2007 | |||||||
| x Flolan | Pulmonary hypertension | On the market | Gilead Sciences | Flolan | ||||
| x Focalin | Attention-deficit hyperactivity disorder | On the market | 7,340,000 | 2006 | Celgene |
Focalin is a brand-name for dexmethylphenidate as marketed by Novartis. For information on the drug's chemical and pharmaceutical properties, see dexmethylphenidate.
Focalin is approved in the United States for the treatment of attention deficit...
|
Focalin | |
| 4,210,000 | 2005 | |||||||
| 5,654,000 | 2007 | |||||||
| x Alendronate |
|
Postmenopausal osteoporosis | On the market | 3,134,400,000 | 2006 | Merck & Co. |
Alendronic acid (INN) or alendronate sodium (USAN, sold as Fosamax by Merck) is a bisphosphonate drug used for osteoporosis and several other bone diseases. It is marketed alone as well as in combination with vitamin D (2,800 U and 5600 U, under the...
|
Fosamax |
| 3,191,200,000 | 2005 | |||||||
| 3,049,000,000 | 2007 | |||||||
| x Fumaderm | Psoriasis | On the market | 21,500,000 | 2007 | Biogen Idec | Fumaderm | ||
| 9,500,000 | 2006 | |||||||
| x Tiagabine |
|
Partial Seizure | On the market | 59,287,000 | 2006 | Cephalon |
Tiagabine (pronounced /taɪˈæɡəbiːn]/) is an anti-convulsive medication produced by Cephalon and marketed under the brand name Gabitril. The drug was discovered at Novo Nordisk in Denmark in 1988 and was co-developed with Abbott. After a period of co...
|
Gabitril |
| 57,310,000 | 2007 | |||||||
| 72,258,000 | 2005 | |||||||
| x Gardasil |
|
Human papillomavirus infection | On the market | 1,480,600,000 | 2007 | Merck & Co. |
Gardasil (Merck & Co.), also known as Gardisil or Silgard, is a vaccine to prevent certain types of human papillomavirus (HPV), specifically HPV types 16, 18, 6, and 11. HPV types 16 and 18 currently cause about 70% of cervical, 26% of head and neck...
|
Gardasil |
| 234,800,000 | 2006 | |||||||
| x Genotropin | Growth hormone treatment | On the market | 795,000,000 | 2006 | Pfizer | Genotropin | ||
| 808,000,000 | 2005 | |||||||
| 843,000,000 | 2007 | |||||||
| x Acarbose | Diabetes mellitus type 2 | On the market | 308,000,000 | 2006 | Bayer |
Acarbose is an anti-diabetic drug used to treat type 2 diabetes mellitus and, in some countries, prediabetes. It is sold in Europe under the brand name Glucobay (Bayer AG), in North America as Precose (Bayer Pharmaceuticals), and in Canada as...
|
Glucobay | |
| 298,000,000 | 2007 | |||||||
| x Adefovir |
|
Hepatitis B | On the market | 230,531,000 | 2006 | Gilead Sciences |
Adefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon and Hepsera, is an orally-administered nucleotide analog reverse transcriptase inhibitor (ntRTI).
It is used for treatment of hepatitis B.
It is a failed treatment for HIV...
|
Hepsera |
| 302,722,000 | 2007 | |||||||
